UnitedHealth backs Gilead's Harvoni as preferred hepatitis C treatment

(Reuters) - UnitedHealth Group Inc on Wednesday backed Gilead Sciences Inc's hepatitis C treatment Harvoni on its 2015 commercial drug coverage list over a new competitor, Viekira Pak from AbbVie Inc. The drug coverage list, which is effective Feb. 1, applies to all of the firm's commercial fully insured customers who use its Optum RX pharmacy benefit manager and self-insured customers such as large employers who follow the drug list. The update to the formulary, available on the company's website, applies to its Medicaid, Medicare and military contracts as well.



via Health News Headlines - Yahoo News http://ift.tt/15UVM4j